Bipolar disorder, also known as manic-depressive illness, is a mental health condition that causes extreme mood swings that alternate between periods of mania or hypomania (elevated or irritable mood, increased energy, decreased need for sleep) and depression (low mood, loss of interest or pleasure in activities, feelings of worthlessness or guilt, changes in appetite and sleep patterns, thoughts of death or suicide). It typically begins in early adulthood and affects both men and women.
Bipolar disorder is classified into different types based on the severity and frequency of episodes. These include:
- Bipolar I disorder: This involves episodes of mania that last at least seven days or are severe enough to require hospitalization, as well as periods of depression.
- Bipolar II disorder: This involves periods of hypomania (a milder form of mania) that alternate with periods of depression.
- Cyclothymic disorder: This involves periods of hypomania and mild depression that last for at least two years.
The exact cause of bipolar disorder is not known, but it's believed to be a combination of genetic, environmental, and biological factors. It typically begins in late adolescence or early adulthood and affects both men and women.
Treatment for bipolar disorder usually involves a combination of medication, psychotherapy, and lifestyle changes. Medications used to treat bipolar disorder include mood stabilizers, antipsychotics, and antidepressants. Psychotherapy can help individuals learn coping skills and manage symptoms, while lifestyle changes such as regular exercise, a healthy diet, and getting enough sleep can also be helpful in managing symptoms.
Samarpan offers bipolar disorder treatment in Mumbai. If you or someone you know is experiencing symptoms of bipolar disorder, it's important to seek professional help from a mental health provider. With proper treatment, many individuals with bipolar disorder can lead healthy and productive lives.
Market InsightsThe growing awareness surrounding mental illnesses has resulted in a huge demand for associated diagnosis and treatment.
Market Research Future (MRFR) has released its latest report on the global bipolar disorder and treatment market which divulges various critical market figures.
Changing lifestyles, socio-economic factors and the rapidly changing culture have led to increased diagnosis of mood disorders.
Over 5.7 million individuals suffer from bipolar disorder in the U.S.; this number is far more substantial across the globe.
Advancements are being made in technology which monitors patient health and can keep track of physical markets which represent mood swings or associated symptoms such as anxiety.Market SegmentationThe segmentation analysis of the Bipolar Disorders Treatment Market has been performed on the basis of drug type, treatment, and region.
On the basis of drug type, the market is segmented to include antidepressant drugs, anti-anxiety drugs, mood stabilizers, atypical antipsychotics, and anticonvulsants.Based on treatment, the market is segmented into transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), and others.
Bipolar Disorders Treatment Market Research Report: Information by Drug Type (Mood Stabilizer, Anticonvulsant, Antipsychotic Drug, and Antidepressant Drug), Mechanism of Action (Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitor, Monoamine Oxidase Inhibitors, Beta Blockers, and Tricyclic Antidepressant Drug), End User (Hospitals and Clinics, Multispecialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2027OverviewThe global bipolar disorders and treatment market is growing with the rapid pace; mainly due to the increasing stress in life.
According to a recent study report published by the Market Research Future, The global bipolar disorders and treatment market is booming and expected to gain prominence over the forecast period growing rapidly .The market is forecasted to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2022).
Bipolar disorder, called manic depression, which is a mental health condition that causes extreme mood swings includes emotional highs (mania or hypomania) and lows (depression).
Bipolar I is considered by one or more manic episodes or mixed episodes.
Bipolar II disorder are generally diagnosed after one or more major depressive episodes and at least one episode of hypomania, with possible periods of level mood between episodes.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1566 Global Bipolar Disorders and Treatment Market - Competitive AnalysisAstraZeneca (U.K), Bristol-Myers Squibb (U.S), Eli Lilly and Company (U.S), GlaxoSmithKline PLC (U.K), Allergan (U.S), Janssen Pharmaceuticals (Belgium), Dainippon Sumitomo Pharma Co., Ltd (Japan), Lundbeck (Denmark), Abbott (U.S.), Cephalon Inc. (Teva Phamaceuticals), Dainippon Sumitomo Pharma Co. Ltd., Forest Laboratories Inc. (U.S.), Gedeon Richter PLC (Hungary), Otsuka America Pharmaceutical Inc., (U.S.) Repligen Corporation, (U.S.) and Pfizer Inc. (U.S.) are some of the prominent players at the forefront of competition in the Global Bipolar Disorders and Treatment Market and are profiled in MRFR Analysis.
Based on Phase 3 study data, ABILIFY MAINTENA delayed the time to recurrence of any mood episode in adult patients experiencing a manic episode at screening compared to placebo.March, 2016- Allergan announced availability of VRAYLAR (cariprazine) for treatment of bipolar mania and schizophrenia in adults.
Global Bipolar Disorders Treatment Market Research Report: Information by Drug Type (Mood Stabilizer, Anticonvulsant, Antipsychotic Drug, and Antidepressant Drug), Mechanism of Action (Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitor, Monoamine Oxidase Inhibitors, Beta Blockers, and Tricyclic Antidepressant Drug), End User (Hospitals and Clinics, Multispecialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025Global Market - OverviewThe global bipolar disorders and treatment market is growing with the rapid pace; mainly due to the increasing stress in life.
According to a recent study report published by the Market Research Future, The global bipolar disorders and treatment market is booming and expected to gain prominence over the forecast period growing rapidly .The market is forecasted to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2022).
Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/1566Bipolar disorder, called manic depression, which is a mental health condition that causes extreme mood swings includes emotional highs (mania or hypomania) and lows (depression).
Bipolar I is considered by one or more manic episodes or mixed episodes.
Global Bipolar Disorders and Treatment Market - Competitive AnalysisAstraZeneca (U.K), Bristol-Myers Squibb (U.S), Eli Lilly and Company (U.S), GlaxoSmithKline PLC (U.K), Allergan (U.S), Janssen Pharmaceuticals (Belgium), Dainippon Sumitomo Pharma Co., Ltd (Japan), Lundbeck (Denmark), Abbott (U.S.), Cephalon Inc. (Teva Phamaceuticals), Dainippon Sumitomo Pharma Co. Ltd., Forest Laboratories Inc. (U.S.), Gedeon Richter PLC (Hungary), Otsuka America Pharmaceutical Inc., (U.S.) Repligen Corporation, (U.S.) and Pfizer Inc. (U.S.) are some of the prominent players at the forefront of competition in the Global Bipolar Disorders and Treatment Market and are profiled in MRFR Analysis.July, 2017- Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced ABILIFY MAINTENA (Aripiprazole) injectable suspension whcih is approved by U.S. FDA for maintenance monotherapy treatment of Bipolar I disorder.
Based on Phase 3 study data, ABILIFY MAINTENA delayed the time to recurrence of any mood episode in adult patients experiencing a manic episode at screening compared to placebo.March, 2016- Allergan announced availability of VRAYLAR (cariprazine) for treatment of bipolar mania and schizophrenia in adults.
